Abstract:Background: Epigenetic regulation has been verified as a key mechanism in tumorigenesis. SET and MYND domain-containing protein 3 (SMYD3), a histone methyltransferase, is a promising epigenetic therapeutic target and is overexpressed in numerous human tumors. SMYD3 can promote oncogenic progression by methylating lysines to integrate cytoplasmic kinase signaling cascades or by methylating histone lysines to regulate specific gene transcription. However, the exact role of SMYD3 in the progression of ovarian cancer is still unknown. Methods: Immunohistochemistry was employed to test SMYD3 expression in ovarian cancer tissues from clinical patients. CCK-8 assay, Real-time cell analysis (RTCA), colony formation assay, cell cycle and apoptosis tested by Flow cytometer were employed to test the effects of SMYD3 on cell proliferation and apoptosis in ovarian cancer cell lines. A PCR array was used to identify the downstream targets of SMYD3. And, PCR and Western blot were used to verify their expression. The binding of SMYD3 on the promoter of target genes were tested by ChIP assays. We also use nude mice subcutaneous tumor model and patient-derived xenograft (PDX) model to investigate the tumor promotive function of SMYD3 in vivo. Results: SMYD3 expression was higher in ovarian cancer tissues and cell lines than in normal ovarian epithelial tissue and human ovarian surface epithelial cells (HOSEpiC). After silencing SMYD3, the proliferation of ovarian cancer cells was significantly inhibited in vitro. In addition, the SMYD3-specific small-molecule inhibitor BCI-121 suppressed ovarian cancer cell proliferation. Downregulation of SMYD3 led to S phase arrest and increased the cell apoptosis rate. Furthermore, a PCR array revealed that SMYD3 knockdown caused the upregulation of the cyclin-dependent kinase (CDK) inhibitors CDKN2A (p16INK4), CDKN2B (p15INK4B), CDKN3 and CDC25A, which may be responsible for the S phase arrest. In addition, the upregulation of CD40LG and downregulation of BIRC3 may explain the increased cell apoptosis rate after silencing SMYD3. We also discovered that SMYD3 bound on the promoter of CDKN2A and down-regulated its expression by triple-methylating H4K20. In addition, SMYD3 bound on the promoter of BIRC3 and up-regulated its expression by triple-methylating H3K4. Finally, knocking down SMYD3 could inhibit ovarian cancer growth in nude mice subcutaneous tumor model and PDX model. Conclusion: Our results demonstrated that SMYD3 was overexpressed in ovarian cancer and contributes to the regulation of tumor proliferation and apoptosis via SMYD3-H4K20me3-CDKN2A pathway and SMYD3-H3K4me3-BIRC3 pathway. Thus, SMYD3 is a promising epigenetic therapeutic target for ovarian cancer.

TET3 inhibits TGF-β1-induced epithelial-mesenchymal transition by demethylating miR-30d precursor gene in ovarian cancer cells

Methyl-CpG-binding Domain 3 Inhibits Epithelial–mesenchymal Transition in Pancreatic Cancer Cells Via TGF-β/Smad Signalling

Increased expression of TET3 predicts unfavorable prognosis in patients with ovarian cancer-a bioinformatics integrative analysis

Effects of Dynein Light Chain Tctex-type 3 on the Biological Behavior of Ovarian Cancer

TET3 Protein Represses Proliferation of the MG-63 Human Osteosarcoma Cell Line by Regulating DNA Demethylation: an Epigenetic Study

Overexpression of SMYD3 in Ovarian Cancer is Associated with Ovarian Cancer Proliferation and Apoptosis via Methylating H3K4 and H4K20

TPPP3 Inhibits the Proliferation, Invasion and Migration of Endometrial Carcinoma Targeted with Mir-1827

METTL3 Promotes the Initiation and Metastasis of Ovarian Cancer by Inhibiting CCNG2 Expression Via Promoting the Maturation of Pri-Microrna-1246

TMED3 stabilizes SMAD2 by counteracting NEDD4‐mediated ubiquitination to promote ovarian cancer

TET 3 and BRCA 1 co-repress EZH 2 to inhibit the aggressive behavior of breast cancer cells

TET1 promotes cisplatin-resistance via demethylating the vimentin promoter in ovarian cancer.

Tripartite-motif 3 represses ovarian cancer progression by downregulating lactate dehydrogenase A and inhibiting AKT signaling

Effect of Down-Regulated Transcriptional Repressor ZEB1 on the Epithelial-Mesenchymal Transition of Ovarian Cancer Cells

Mir-30b-3p affects the migration and invasion function of ovarian cancer cells by targeting the CTHRC1 gene

Downregulation of TGF-β1 Suppressed Proliferation and Increased Chemosensitivity of Ovarian Cancer Cells by Promoting BRCA1/Smad3 Signaling

METTL3 Promotes Ovarian Carcinoma Growth and Invasion Through the Regulation of AXL Translation and Epithelial to Mesenchymal Transition.

MicroRNA-455-3p Mediates GATA3 Tumor Suppression in Mammary Epithelial Cells by Inhibiting TGF-β Signaling

Upregulation of miR-874-3p and miR-874-5p inhibits epithelial ovarian cancer malignancy via SIK2.

20(S)-Rg3 Blocked Epithelial-Mesenchymal Transition Through DNMT3A/miR-145/FSCN1 in Ovarian Cancer

Downregulation of DNMT3A Attenuates the Warburg Effect, Proliferation, and Invasion via Promoting the Inhibition of miR-603 on HK2 in Ovarian Cancer

A Double-Negative Feedback Interaction Between MicroRNA-29b and DNMT3A/3B Contributes to Ovarian Cancer Progression